Home › Compare › DPSIP vs ABBV
DPSIP yields 392.16% · ABBV yields 3.06%● Live data
📍 DPSIP pulled ahead of the other in Year 1
Combined, DPSIP + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of DPSIP + ABBV for your $10,000?
Decisionpoint Systems, Inc. provides and integrates enterprise mobility and wireless applications solutions that delivers improved productivity and operational advantages to its clients by helping to move business decision points closer to its customers. It makes enterprise software applications accessible to the front-line worker anytime, anywhere. The company utilizes wireless, mobility, and RFID technologies. It sells, installs, deploys, and repairs mobile computing and wireless systems, such as mobile computers and application software; and related data capture equipment, including bar code scanners and radio frequency identification readers for the retail, warehousing and distribution, healthcare, wholesale distribution, and field sales and service industries. The company also offers lifecycle management, and project management and deployment services; and managed services, such as consulting, technology acquisition, project management, software integration and development, deployment, repair services, service desk, and reverse logistics and end of life disposal services, as well as OnPoint Service Hub, a customer service portal that provides customers real-time asset management and tracking information. In addition, it provides MobileConductor, a software platform that provides complete in-vehicles solutions; VizeTrace, a software platform that manages RFID installations; and custom software development services, as well as resells specialized independent software vendors applications. The company is headquartered in Laguna Hills, California.
Full DPSIP Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.